Which fixed‑dose combination of a thiazide diuretic and an ACE inhibitor is optimal to start for hypertension?

Optimal Fixed-Dose Combination for Initial Hypertension Treatment

For most patients starting combination therapy for hypertension, initiate with an ACE inhibitor (or ARB) combined with a thiazide-like diuretic (chlorthalidone 12.5–25 mg or indapamide 1.25–2.5 mg daily) in a single-pill formulation.

Guideline Consensus on Preferred Two-Drug Combinations

Multiple international hypertension guidelines uniformly recommend specific two-drug combinations as first-line therapy 1, 2, 3:

• Thiazide diuretic + ACE inhibitor is explicitly listed as an effective and well-tolerated combination by the 2007 ESH/ESC guidelines 2
• Thiazide diuretic + ARB is equally preferred and appears in all major guideline recommendations 1, 2, 3
• The 2024 ESC guidelines specifically state that preferred combinations are a RAS blocker (ACE inhibitor or ARB) with either a dihydropyridine CCB or a thiazide/thiazide-like diuretic 3

Why Thiazide-Like Diuretics Are Superior

Chlorthalidone and indapamide are strongly preferred over hydrochlorothiazide because they provide superior cardiovascular event reduction 4, 3:

• A meta-analysis of 21 randomized trials demonstrated that thiazide-like diuretics resulted in an additional 12% risk reduction for cardiovascular events (P = 0.049) and 21% risk reduction in heart failure (P = 0.023) compared with traditional thiazides 4
• Only thiazide-like diuretics reduced coronary events and all-cause mortality when compared with placebo 4
• The 2024 ESC guidelines explicitly recommend thiazide-like diuretics (chlorthalidone or indapamide) as first-line agents 3

Pharmacologic Synergy of ACE Inhibitor + Thiazide

This combination provides complementary mechanisms of action 5, 6:

• Thiazide diuretics stimulate the renin-angiotensin-aldosterone system, which is counter-acted by the concurrent ACE inhibitor, producing an additive blood pressure-lowering effect 6
• The combination is safe and well-tolerated with a lower rate of ankle edema compared to ACE inhibitor + calcium channel blocker combinations 5

Evidence from Major Clinical Trials

Real-world effectiveness data strongly support this combination 7:

• A retrospective analysis of 17,568 hypertensive patients in Taiwan showed that fixed-dose combinations of RAS inhibitor + thiazide diuretic reduced major adverse cardiovascular events (HR 0.85; 95% CI 0.74–0.97; P = 0.017) compared with free-combination regimens 7
• The combination also reduced hospitalization for heart failure and initiation of dialysis 7
• Fixed-dose combinations improved medication adherence, with outcome benefits primarily driven by reduced cardiovascular and renal events in patients with poor adherence 7

Specific Dosing Recommendations

Start with these evidence-based regimens 8, 3:

• Benazepril 10 mg + hydrochlorothiazide 12.5 mg (Lotensin HCT) 8
• Lisinopril 10 mg + hydrochlorothiazide 12.5 mg (Prinzide, Zestoretic) 8
• Enalapril 5 mg + hydrochlorothiazide 12.5 mg (Vaseretic) 8
• For superior outcomes, substitute chlorthalidone 12.5–25 mg or indapamide 1.25–2.5 mg in place of hydrochlorothiazide 4, 3

Alternative: ARB + Thiazide Combinations

If ACE inhibitors are not tolerated (due to cough or angioedema), ARB + thiazide combinations are equally effective 1, 8, 3:

• Losartan 50 mg + hydrochlorothiazide 12.5 mg (Hyzaar) 8
• Valsartan 80 mg + hydrochlorothiazide 12.5 mg (Diovan-HCT) 8
• Candesartan 16 mg + hydrochlorothiazide 12.5 mg (Atacand HCT) 8

When to Choose ACE Inhibitor + CCB Instead

The ACE inhibitor + calcium channel blocker combination is supported by the ACCOMPLISH trial 4:

• Benazepril + amlodipine reduced the composite of cardiovascular death and major adverse cardiovascular events compared with benazepril + hydrochlorothiazide (HR 0.80; 95% CI 0.72–0.90) 4
• However, this trial enrolled high-risk patients, and the thiazide dose used (hydrochlorothiazide) was suboptimal compared to thiazide-like agents 4

Critical Pitfalls to Avoid

Never combine two RAS blockers (ACE inhibitor + ARB or either with aliskiren), as this increases cardiovascular and renal risk without added benefit 3, 6:

• High-quality RCT data demonstrate that simultaneous administration of RAS blockers increases cardiovascular and renal risk 6
• The 2024 ESC guidelines explicitly state that combining two RAS blockers is not recommended 3

Avoid beta-blocker + thiazide combinations when possible, as they are associated with higher incidence of new-onset diabetes 2:

• The 2007 ESH/ESC guidelines note that this combination should be avoided in patients with metabolic syndrome and when there is high risk of incident diabetes 2

Ensure adequate thiazide dosing 8, 6:

• Many fixed-dose combination pills contain subtherapeutic amounts of hydrochlorothiazide (<25 mg), which may explain poor blood pressure control 6
• The doses used in successful morbidity trials were 25–50 mg of hydrochlorothiazide or 12.5–25 mg of chlorthalidone 8

Monitoring Requirements

Check serum creatinine and potassium 2–4 weeks after starting therapy, then at least annually 3:

• Thiazides can cause mild hyperuricemia and hypokalemia 8
• Hypokalemia should be avoided in patients treated with thiazide diuretic monotherapy 9
• In the SHEP trial, positive benefits of diuretic therapy were not apparent when serum potassium levels were below 3.5 mmol/L 8

Escalation to Triple Therapy

If blood pressure remains ≥140/90 mmHg after 3 months on dual therapy, add a third agent 3, 10:

• The preferred triple regimen is ACE inhibitor (or ARB) + calcium channel blocker + thiazide-like diuretic 1, 3, 10
• This combination is uniformly recommended by JNC 8, ASH/ISH, NICE, Taiwan, French, ESC, and ISH guidelines 1, 10
• Preferably use a single-pill formulation to improve adherence 3, 10